Iridex Corporation Highlights Cyclo G6® Laser System with Over 180,000 Glaucoma Patients Treated Globally

Mar 11, 2025 11:11 CST Updated 11:11

IRIDEX

Medical Device R&D and Manufacturer

Robotrak Technologies

Ophthalmic Medical Device R&D Developer

Source: Eye Future；Editor: Sophia

Reprint requirements: Can be reprinted 24 hours after the first publication, source must be credited.

Invitation | First Global Ophthalmology Conference, Ophthalmology White Paper, Innovation Awards Ceremony | GOC2025

For some patients with refractory glaucoma whose intraocular pressure still cannot be effectively controlled after multiple conventional anti-glaucoma surgeries (regardless of whether the maximum dose of medication has been used), traditional ciliary body destructive surgeries (including cyclocryotherapy, transscleral cyclophotocoagulation, etc.) are usually chosen in clinical practice, butThe postoperative reaction was severe, and there were many complications., such as persistent hypotony, endophthalmitis, decreased vision, vitreous hemorrhage, and phthisis bulbi, etc.

MicroPulse Transscleral Laser Therapy (mTLT) is a novel, non-invasive, and repeatable minimally invasive glaucoma treatment., Non-lethal destruction of the ciliary body is achieved through micropulse laser via the sclera, which helps reduce intraocular pressure.Suitable for the treatment of various mild to severe primary open-angle glaucoma (POAG), primary angle-closure glaucoma (PACG), and refractory glaucoma.。

Recently,Iridex Corporation(Nasdaq: IRIX) announced a landmark peer-reviewed study. This studyHighlighted the sustained safety and efficacy of micropulse transscleral laser in treating primary and secondary glaucoma over 5 years.. The treatment uses IRIDEX.Cyclo G6® Laser (Semiconductor Laser Therapy Device) and MicroPulse P3® Probe, which was approved by the U.S. FDA in early 2017 and received approval to enter China in May 2022.

The ProductGlobal TreatmentExceed180,000Glaucoma Patients, GlobalMore than 80Recognized and Used by Top National Hospitals, can be used before or after other glaucoma treatments or in combination with them.

IRIDEX Cyclo G6 Laser Equipped with MicroPulse P3 Infrared Probe

According to statistics from the U.S.-based research firm Fortune Business, the global market for laser and other photonic medical devices was approximately $4.15 billion in 2021.The compound annual growth rate is expected to be 16.8% in the next eight years.(Data includes only equipment, excluding services).

At present, the laser and other optoelectronic medical devices in China are mainly imported, and the localization ratio of key devices is relatively low. In the market for ophthalmic laser treatment equipment,ZEISS, IRIDEX, Robotrak TechnologiesRanking in the top three.In the field of ophthalmic semiconductor laser treatment machines,Only five manufacturers' products have been approved in China., namely IRIDEX, Nidek, Guangtai Healthcare, Chengxian Technology, and the domestically produced company Robotrak Technologies.

# Research Details

Research Methods

This study was conducted by Dr. Ronald de Crom and colleagues from the Ophthalmology Clinic at Maastricht University in the Netherlands,The study involved 165 eyes.(Including eyes before and after cataract surgery) that were treated between 2016 and 2019, of which 112 eyes completed the 5-year follow-up.

Research Results

The average intraocular pressure (IOP) was reduced by 32.5%., statistically significant (p<0.001).
A significant reduction in the need for IOP-lowering drugs（p<0.005）。
Low complication rate, suitable for a wide range of glaucoma types and severities.
During the 5-year follow-up period,Only 38% of eyes required retreatment.Patients who underwent repeat treatments achieved a similar level of success as those receiving initial treatment, with no significant increase in the risk of complications.

Clinical Significance

These findings suggest that MicroPulse TLT can serve as a viable alternative to invasive, incisional glaucoma surgery.Repeated treatments can effectively reduce intraocular pressure and decrease the number of antiglaucoma medications used.。

# Cyclo G6 Cyclotronic Laser

Cyclo G6® Laser

Equipped with unique MicroPulse technologyThis technology cuts a continuous wave laser beam into a series of tiny, repetitive, low-energy pulses, allowing the tissue time to cool between laser pulses.Minimize damage to surrounding tissues，Reduce Risk.

The product consists of a laser main unit, a foot pedal switch, and a disposable laser fiber optic cable, used for reducing intraocular pressure in glaucoma patients whose eye pressure cannot be controlled by medication or surgery. The fiber optic cable is composed of a connector, fiber transmission body, and application end, available in two models: G probe and MicroPulse P3.

MicroPulse P3 Second Generation Probe

The second-generation MP3 probe is more compact and suitable for a wider range of patients.

Retracted Surface and Smooth Design, conforming to the curvature of the patient's eyeball surface, ensuring the safety of the treatment process; the retracted fiber probe tip and liquid chamber ensure sufficient space for coupling agent, making the energy uniform and consistent during treatment.Rabbit Ear Open Angle Design, conforming to the curvature of the limbus, facilitating precise alignment and operation by physicians, ensuring therapeutic efficacy.

Cyclo G6 Laser and MicroPulse P3 Delivery DeviceUsing an infrared semiconductor laser with a wavelength of 810nm, dividing the continuous energy wave into a series of pulses, with 31.3% of the time (duty cycle) in the "on" state and 68.7% of the time in the "off" state during each pulse, minimizing tissue temperature rise and coagulation damage.

MicroPulse technology delivers less energy over time and, when combined with a scanning method, compared to traditional transscleral cyclophotocoagulation (TS-CPC),Its energy distribution is more uniform, and mTLT has a lower temperature and better heat control, which helps reduce the occurrence of complications.。

Surgical Procedure

Peribulbar or retrobulbar anesthesia can be used during anesthesia.
An appropriate amount of viscous liquid coupling agent (e.g., methylcellulose) is applied to the conjunctiva.A drop of liquid is applied to the front surface of the probe, ensuring the liquid covers both the eye and the probe tip.
Set the laser to the following mode: Power 2000mW; Duty Cycle 31.3% (0.5ms ON & 1.1ms OFF).Translate the MP3 probe along the limbus for 15 seconds over a 150-degree arc of one hemi-eye or for 7 seconds over a 75-degree angle (1/4 of the eye), repeat 5-6 times.80 seconds per hemisphere, totaling 160 seconds of pulse envelope.
Check if the probe direction is correct. The circular surface at the probe notch should face the limbus, and the flat surface should face the eyelid.
Place the probe 1mm away from the limbus and tilt it towards the center of the eyeball. See Figure A.
By sweeping/sliding and using appropriate pressure (similar to the pressure of writing with a pen on paper), move the probe over the upper and lower parts of the eyeball (avoiding the 3 and 9 o'clock positions), as shown in Figures B and C. Continue this motion consistently throughout the entire treatment process. At the same time, remember to use a viscous or liquid interface to prevent laser beam diffusion and ensure proper energy transmission.
Complete a 160-second treatment session (80 seconds each for the upper and lower parts of the eyeball). After laser treatment, apply anti-inflammatory eye drops for 1 to 2 weeks postoperatively.

# About IRIDEX

Iridex Corporation was founded in 1989, originally named IRIS Medical Instruments, and renamed Iridex Corporation in 1995, focusing onDeveloper, manufacturer, and seller of ophthalmic medical systems, delivery devices, and disposable instruments, for the treatment of glaucoma and retinal diseases。

Provided by the companyLaser-based medical delivery devices and surgical probes for the treatment of glaucoma and retinal diseases. Under itsThe product also includesIQ 532® Laser and IQ 577® Laser Photocoagulation Systems,Used to treat retinal diseases such as diabetic macular edema.

GOC2025 Zone

Registration: First Global Ophthalmology Conference | Global Ophthalmology Conference 2025

IfBooth/White Paper/Speech SharingIf you are interested in the above content, please feel free to contact us.

Partner:Xianwei Medical | Optotek Medical| Bangxun Pharmaceuticals |Intalight赛炜

Contact information is as follows:

Work WeChat ID：suribot22

Phone Number:13552754250

You can also contact the editor-in-chief Zhao Qing, Alice, Jacky, Ziana and other staff members of the Siyu team directly.

Ophthalmology Solutions Case

Cataract Total Solution #SightMed

Comprehensive Vision Care Solutions #Johnson & Johnson

Glaucoma Comprehensive Solution #Haisi Gaidé

Ophthalmic Instruments Industry Research

Latest Industry Research | A Comprehensive Overview of the OCT Industry Landscape

An Overview of the Development History of Fundus Cameras

An Overview of Intraocular Lenses

An Overview of Digital Therapeutics in Ophthalmology

An Overview of the Orthokeratology Lens Track